€12.9M in Equity Financing: Quantum Genomics makes investor's hearts beat
​Quantum Genomics is a biopharmaceutical company dedicated to the development of innovative therapies for cardiovascular diseases of unmet medical needs. The French company successfully completed a €11.2M public offering on Alternext Paris. The offering was a tremendous success among institutional and individual investors, who showed a strong interest in a company developing potential blockbuster drugs. The proceeds will allow Quantum Genomics to continue the clinical programs in hypertension and congestive heart failure. Their most advanced drug candidate, QGC001, will soon enter a Phase IIa trial in hypertension. The drug is a Brain Aminopeptidase A Inhibitor (BAPAIs), a new class of molecules developed by the company for cardiovascular diseases, using a novel mechanism of action. Should the trial be successful, it would be the first proof of efficacy of BAPAIs in human patients. We adjusted Quantum Genomics' valuation to €8.59/share following the offering and subsequent dilution.
Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.